Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Dow
Johnson and Johnson
Medtronic
Express Scripts

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,220,767

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,220,767 protect, and when does it expire?

Patent 7,220,767 protects ZOMIG and is included in one NDA.

Protection for ZOMIG has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-two patent family members in twenty-eight countries.

Summary for Patent: 7,220,767
Title:Pharmaceutical formulations containing zolmitriptan
Abstract:A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
Inventor(s): Dearn; Alan Roy (Hertfordshire, GB), Williamson; Sarah Louise (Hertfordshire, GB), Summers; John Simon (Hertfordshire, GB), Coomber; Trevor John (Hertfordshire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/854,959
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,220,767
Patent Claim Types:
see list of patent claims
Composition; Formulation; Device;

Drugs Protected by US Patent 7,220,767

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-003 Sep 16, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-004 Sep 30, 2003 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,220,767

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9928578.5Dec 03, 1999

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Colorcon
McKinsey
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.